Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience

Key Points

• The aim is to review the clinical experiences associated with daratumumab treatment in patients with relapsed refractory multiple myeloma.
• Review of clinical data and experiences related to daratumumab
• Discussion of patient outcomes and treatment responses
• Analysis of treatment efficacy and safety profiles
• Daratumumab shows significant efficacy in treating relapsed refractory multiple myeloma
• Patient response rates indicate improvement in clinical outcomes
• Adverse effects are manageable with careful monitoring